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Pro inflammatory stimuli enhance 
the immunosuppressive functions 
of adipose mesenchymal stem cells-
derived exosomes
Rossana Domenis  1, Adriana Cifù1, Sara Quaglia1, Cinzia Pistis1, Massimo Moretti2, 
Annalisa Vicario2, Pier Camillo Parodi4, Martina Fabris1,3, Kayvan R. Niazi5,  
Patrick Soon-Shiong5 & Francesco Curcio1,3
The predominant mechanism by which adipose mesenchymal stem cells (AMSCs) participate 
to tissue repair is through a paracrine activity and their communication with the inflammatory 
microenvironment is essential part of this process. This hypothesis has been strengthened by the 
recent discovery that stem cells release not only soluble factors but also extracellular vesicles, which 
elicit similar biological activity to the stem cells themselves. We demonstrated that the treatment 
with inflammatory cytokines increases the immunosuppressive and anti-inflammatory potential of 
AMSCs-derived exosomes, which acquire the ability to shift macrophages from M1 to M2 phenotype 
by shuttling miRNA regulating macrophages polarization. This suggests that the immunomodulatory 
properties of AMSCs-derived exosomes may be not constitutive, but are instead induced by the 
inflammatory microenvironment.
Mesenchymal stem cells (MSCs) could be easily isolated from adult tissue and, by virtue of their large ex vivo 
expansion capacity, multipotency and immunosuppressive activity, have become a popular experimental ther-
apeutic agent in many human diseases. Of note, the capacity of MSCs to secrete a variety of trophic factors with 
different functions has motivated the interest of evaluating their local or systemic injection to stimulate tissue 
repair in different pathologies1.
The anti-inflammatory properties of MSCs has been linked to their immunosuppressive potential2.
MSCs are able to regulate the immune response suppressing T-cell proliferation, cytokines secretion and cyto-
toxicity, regulating the functions of regulatory T cells, inhibiting proliferation of B cells, and maturation, activa-
tion and antigen presentation of dendritic cells and interleukin-2 (IL-2)-induced natural killer cell activation (for 
review see3).
Intriguingly, it has been also proposed that MSCs immunosuppressive ability is not constitutive; instead, it is 
induced by inflammatory cytokines, such as those present in the inflammatory microenvironment4. Exposure of 
MSCs to IFNγ increases the immune suppressive activity by stimulating the production of inhibitors of inflamma-
tion, such as indoleamine-pyrrole 2,3-dioxygenase (IDO)5, Factor H6, prostaglandin E2 (PGE2)7, TGFβ and HGF8. 
Another inflammatory mediator known to induce regenerative activities in MSCs is the macrophage-derived 
cytokine TNFα, which endowed the cells with superior angiogenetic activity in vitro as well as in vivo in an ani-
mal model of critical limb ischemia9.
Although the underlying mechanisms of MSCs immunomodulation is still to be elucidated, they are likely 
mediated both by soluble factors2 and cell-contact-dependent mechanisms3.
Recently, it has been proposed that the predominant way by which MSCs participate to tissue repair is through 
a paracrine activity10: in animal models, conditioned media reproduces benefits reported with the direct injection 
of MSCs11. The paracrine hypothesis has been strengthened by the recent discovery that stem cells release not only 
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soluble factors but also extracellular vesicles, which elicit similar biological activity to the stem cells themselves12. 
The most prominent of the extracellular vesicles are exosomes, a class of small (40–100 nm) vesicles derived from 
endosomes through the invagination of the endosomal membrane. MSCs-derived exosomes release and transfer 
proteins, bio-active lipids and nucleic acid cargo, thus being able to induce phenotypic and functional changes in 
the recipient cells and promote the activation of regenerative programs13,14.
The regenerative activities of MSCs-derived exosomes are a subject of ongoing investigation. MSCs-derived 
exosomes are thought to have similar functions to MSCs such as repairing and regeneration of injured tissues, 
but little is known about the immunomodulatory effect of these vesicles and results reported in literature are 
discordant.
It has been demonstrated that MSCs-derived exosomes are able to induce anti-inflammatory IL-10 and 
TGF-β transcripts and attenuate pro-inflammatory IL-1β, IL-6, TNF-α and IL12P40 transcripts in THP-1 
monocytic cell line15 and have an inhibitory effect in the differentiation and activation of T cells16. Moreover, 
MSCs-derived exosomes extracted from healthy donors’ bone marrow are able to suppress PBMCs secretion 
of pro-inflammatory factors such as TNF-α and IL-1β and increase the concentration of the anti-inflammatory 
cytokine TGF-β. In addition, these vesicles may induce conversion of T helper type 1 (Th1) into T helper type 2 
(Th2) cells and reduce potential of T cells to differentiate into IL-17-producing effector T cells (Th17)17. On the 
other hands, it has been also reported that exosomes secreted by MSCs fail to suppress lymphocytes prolifera-
tion18, hypothesizing that cell-cell contact plays an important role on their immunosuppressive potential.
In this study, we investigated the immunomodulatory properties of exosomes released from adipose mesen-
chymal stem cells (AMSCs) under stimulation with IFNγ and TNFα inflammatory cytokines in order to evaluate 
the influence of inflammatory environment on exosomes production and functions.
Results
Effect of the stimulation with cytokines IFNγ and TNFα on AMSCs. AMSCs isolated by adipose 
tissues were tested using specific surface markers by flow cytometry: the tested AMSCs were almost completely 
negative for the hematopoietic markers (CD34 and CD45) and >95% positive for the mesenchymal stem cells 
markers (CD29, CD73, CD90 and CD105) (Supplementary Figure 1). To determine whether inflammatory 
stimuli may affect morphology and viability of AMSCs, cells were cultured in the presence of IFNγ/TNFα at 
concentration of 10, 20 and 40 ng/ml for 48 hours. We observed that the treatment with cytokines induced mor-
phological changes, since the cells become more elongated and are characterized by an irregular shape (Fig. 1A). 
The incubation with cytokines decreased AMSCs proliferation in a concentration-dependent manner (Fig. 1B), 
while cells viability was not affected (Fig. 1C).
We next examined the effect of inflammatory stimuli on the release of immunosuppressive factors and 
cytokines/chemokines by AMSCs. Treatment with IFNγ/TNFα increased the expression of the enzyme IDO 
in a concentration-dependent manner (Fig. 2A), while the release of PGE2 (Fig. 2B), IL-10 (Fig. 2C) and IL-8 
(Fig. 2D) was significantly induced only after treatment with at least 20 ng/ml of the IFNγ/TNFα mixture. Finally, 
IL-6 (Fig. 2E) and CCL-2 (Fig. 2F) upregulation was significant only after treatment with 40 ng/ml of IFNγ/TNFα.
Figure 1. Stimulation with IFNγ/TNFα mixture induces morphological changes and inhibits proliferation of 
AMSCs. (A) Representative phase contrast images (10x magnification) of AMSCs incubated with IFNγ/TNFα 
at concentration of 10, 20 and 40 ng/ml for 48 hours. (B–C) Cell proliferation and viability were determined 
by trypan blue exclusion assay. Columns, mean; bars, SD * significant difference from unstimulated cells; § 
significant difference from treatment with IFNγ/TNFα at concentration of 10 ng/ml, P < 0.05.
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Characterization of AMSCs derived-exosomes after stimulation by pro-inflammatory cytokines. 
AMSCs were pre-treated with IFNγ/TNFα at increasing concentration (10, 20 and 40 ng/ml), then an enriched 
fraction of exosomes was obtained from the supernatants using the Exoquick polymer-based strategy.
As shown in Fig. 3A, AMSCs-derived exosomes and AMSCs lysates expressed the specific exosomal markers 
CD9, CD63, CD81 and TSG101, while no signal was observed for Exoquick-derived supernatant samples, that 
were used as negative control. In order to evaluate the impurities in our exosome preparations, we also evalu-
ated the expression of proteins associated with subcellular compartments, which are supposed to be absent or 
under-represented in exosomes. Our data showed lack of calnexin (endoplasmic reticulum protein) and RISC 
complex (nucleus protein) in exosome fraction, indicating successful enrichment. We also reported a faint band 
for GRP94 (endoplasmic reticulum protein) in the exosomal fraction probably due to a slight contamination by 
apoptotic bodies.
The concentration of AMSCs-derived exosomes was determined measuring the activity of AChE by Exocet 
kit. As reported in Fig. 3B, the mean concentration of exosomes released by untreated cells was 7.6 ± 2.6 × 109 
per million of producing cells. Treatment with cytokines did not influence the number of exosomes released by 
AMSCs.
Finally, the average size of the collected vesicles, determined by qNano technology, was 115 ± 11.5 nm, in 
range with exosomes proper size, and was not influenced by AMSCs cytokines treatment (Fig. 3D).
Figure 2. Stimulation with IFNγ/TNFα mixture induce the expression of immunosuppressive factors, 
cytokines and chemokines in AMSCs. AMSCs were treated with IFNγ/TNFα at concentration of 10, 20 and 
40 ng/ml for 48 h. Expression of IDO was determined by flow cytometry while PGE2 and cytokines/chemokines 
production was measured in supernatants by ELISA kit. Columns, mean; bars, SD, * significant difference 
from unstimulated cells, § significant difference from treatment with IFNγ/TNFα at concentration of 10 ng/ml, 
P < 0.05.
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Exosomes derived from AMSCs pre-activated with pro-inflammatory cytokines induce an anti- 
inflammatory M2 phenotype reverting M1 differentiation. To examine the ability of AMSCs-derived 
exosomes in inducing anti-inflammatory phenotype in macrophages, CD14+ monocytes isolated from PBMCs 
of blood donors were induced to differentiate into M1 macrophages with GM-CSF in presence of exosomes 
isolated from supernatants of AMSCs pre-activated with IFNγ/TNFα. As shown in Fig. 4A, at day 9, control 
monocytes gave rise to “fried egg-shaped” morphology, a typical feature of M1-like macrophages. When mono-
cytes were differentiated in the presence of exosomes obtained from pre-activated AMSCs, some cells displayed 
an elongated, spindle-like morphology, a typical feature of M2 macrophages19. The effect is particularly evident in 
monocytes incubated with exosomes isolated from AMSCs pre-activated with 40 ng/ml of IFNγ/TNFα. Indeed, 
compared to untreated M1-like macrophages, only exosomes isolated from pre-activated AMSCs are able to 
upregulate the expression of the M2 macrophage marker CD163 (Fig. 4B). With regard to CD206 expression, it 
became significant only after treatment with exosomes produced by pre-activated cells with 40 ng/ml of IFNγ/
TNFα (Fig. 4C). In contrast, the expression of the M1 macrophage marker CD80 did not change significantly in 
the presence of AMSCs-derived exosomes (Fig. 4D).
In order to evaluate a possible contamination of IFNγ and TNFα in exosome preparations, the culture medium 
supplemented with cytokines at different concentrations (10, 20 and 40 ng/ml) was treated with Exoquick and 
concentration of IFNγ and TNFα was measured by magnetic beads-based multiplex assay.
Figure 3. Characterization of AMSCs derived–exosomes. (A) Immunoblotting of AMSCs-derived exosomes, 
Exoquick-derived supernatants (SN) and AMSCs lysate for CD9, CD63, CD81 and TSG101 exosomal 
protein and Calnexin, GRP94 and RISC contaminants (cropped images – uncropped originals available 
in Supplementary Figure 2). (B) The concentration of exosomes was quantified measuring the enzymatic 
activity of the exosomal AChE enzyme by Exocet kit. Particles size were quantified by qNano system (D) and a 
representative graph of frequency size distribution is shown (C). Columns, mean; bars, SD.
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Figure 4. Exosomes derived from AMSCs pre-activated with pro-inflammatory cytokines induce an anti-
inflammatory M2 phenotype reverting M1 differentiation. (A) Representative phase contrast microscopic 
images (20x magnification) of monocytes differentiated into macrophages in presence of GM-CSF alone 
(CTRL) or in combination with exosomes isolated from the supernatants of unstimulated (EXO UNSTIM) 
or cytokines-activated (EXO IFNγ/TNFα 10, 20 and 40 ng/ml) AMSCs. The green circles evidence cells 
with elongated, spindle-like morphology, a typical feature of M2 macrophages. Flow cytometry analysis of 
cell surface molecules CD163 (B) CD206 (C) and CD80 (D) on macrophages. The levels of expression are 
presented as median fluorescent intensity (MFI) fold change respect untreated cells. Columns, mean; bars, SD, * 
significant difference from unstimulated cells, P < 0.05.
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We found slightest amounts of IFNγ (0.096 ± 0.003 pg/ml) and TNFα (0.039 ± 0.001 pg/ml), which are min-
imal compared to those used in literature to stimulate monocytes or macrophages. Moreover, we evaluated the 
potential effect of these contaminants during monocytes differentiation, finding that they did not influence 
macrophages polarization in the expression of CD80 (Supplementary Figure 3A) and CD163 (Supplementary 
Figure 3B).
Exosomes derived from AMSCs pre-activated with inflammatory cytokines contained miRNAs 
involved in M2 macrophages polarization. Exosome-associated microRNAs were profiled using small 
RNA next generation sequencing, setting exosomes released by untreated cells as control samples and exosomes 
released by AMSCs treated with 20 ng/ml IFNγ/TNFα as test samples. The fold change was calculated dividing 
the normalized gene expression profile of test samples by the corresponding control samples. The activation with 
cytokines of AMSCs induced, in the released exosomes, the over-expression and the under-expression of 23 dif-
ferent miRNAs (Fig. 5 and Table 1).
Next, we validated the RNA sequencing data focusing on specific miRNAs involved in the regulation of mac-
rophage polarization20. By quantitative RT-PCR, we evaluated the expression of miRNAs regulating the differenti-
ation towards M1 (miR-127-3p and miR-155-5p) or M2 (miR-34a-5p, miR124-3p, miR135b-5p and miR146a-5p) 
phenotypes. Of note, miR-21-5p is able to redirect both M1 and M2 polarization, depending on protein target.
All the miRNAs under investigation were expressed at low level in unstimulated AMSCs-derived exosomes 
(Fig. 6), except for miRNA-124-3p, which was undetectable (data not shown). The expression of miRNA-34 
(Fig. 6A) and miRNA-146 (Fig. 6B) was significantly higher in exosomes produced by AMSCs pre-activated with 
20 and 40 ng/ml IFNγ/TNFα compared to those of untreated cells, while miRNA-21 expression was significantly 
upregulated only for 40 ng/ml cytokine pre-stimulation (Fig. 6C). No difference was observed for the expression 
of miR-135 (Fig. 6D). The expression of miR-127 (Fig. 6E) and miR-155 (Fig. 6F) were significantly increased 
only in exosomes produced by AMSCs activated with the highest (40 ng/ml) cytokine concentration, but at a very 
lesser extent compared to the other described miRNAs.
Finally, to evaluate the downstream effect of miRNA expression upregulation in our AMSC experimental 
model, we choose to analyse the protein expression of some specific miRNA targets in macrophage lysates. In 
particular, we analysed the expression of Notch1, IRAK1 and Sirp-β1 targeted by miR-34a21, miR-14622 and miR-
2123, respectively.
As illustrated in Fig. 6G, IRAK1 expression was dramatically reduced after treatment with exosomes of 
pre-stimulated AMSCs, while the expression of Notch1 was reduced only with exosomes release from cells treated 
with 20 ng/ml of cytokines. The expression of Sirp-β1 was not affected by the treatment with exosomes.
Figure 5. Differential expression of exosomal miRNA. Histograms of the human miRNome expression analysis 
depicting the distribution of differentially expressed miRNA in exosomes produced by AMSCs treated with or 
without 20 ng/ml IFNγ/TNFα. The graph was obtained by plotting the log2 fold change of normalized count of 
under-expressed (green) and over-expressed (red) miRNAs isolated from exosome released by treated cells.
LOST miRNAs GAINED miRNAs
let-7e-5p miR-186-5p miR-30a-3p miR-671-3p miR-100-3p
miR-125b-5p miR-1910-5p miR-335-3p miR-7706 miR-101-3p
miR-134-5p miR-193b-3p miR-382-5p miR-98-5p miR-1246
miR-136-3p miR-197-3p miR-409-3p miR-127-3p
miR-148b-3p miR-19b-3p miR-4677-3p miR-155-5p
miR-150-5p miR-23b-3p miR-532-5p miR-361-5p
miR-151a-5p miR-27b-3p miR-6515-5p miR-411-5p
miR-181b-5p miR-301a-3p miR-654-5p miR-493-3p
Table 1. Loss and gain of miRNAs in exosomes produced by AMSCs treated with or without 20 ng/ml IFNγ/
TNFα.
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Figure 6. Exosomes derived from AMSCs pre-activated with inflammatory cytokines contained miRNA 
involved in M2 macrophages polarization. The concentration of miR-34 (A), miR-127 (B), miR-21 (C), miR-135 
(D), miR-146 (E) and miR-155 (F) was measured in exosomes produced by AMSCs treated with or without 10, 
20 and 40 ng/ml IFNγ/TNFα by qRT–PCR. Columns, mean; bars, SD, * significant difference from exosomes 
of unstimulated cells, P < 0.05. (G) Monocytes were differentiated in macrophages with GM-CSF in presence 
of exosomes isolated from the supernatants of unstimulated (EXO UNSTIM) or cytokines-activated (EXO 
IFNγ/TNFα 10, 20 and 40 ng/ml) AMSCs. Cell lysates were subjected to Western blot analysis with specific 
antibody against to IRAK1, Notch1, Sirp-β1 and β-actin (cropped images – uncropped originals available in 
Supplementary Figure 4).
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Discussion
The unique MSCs immunosuppressive capability make them a promising therapeutic tool to suppress inflam-
mation and to down-regulate the exaggerated immune response causing tissue damage by chronic inflammation 
or autoimmune disorders3,24. On the other hands, accumulating evidences support the notion that MSCs act 
mostly in a paracrine manner, through the release of soluble factors and extracellular vesicles, opening oppor-
tunities for secretome-based therapies, even if the mechanisms are not fully understood and the results remain 
controversial14.
The regenerative potential of MSCs-derived exosomes is a subject of fervent international investigation. In 
fact, a conclusive demonstration that exosomes may exert important immune-regulatory activities should open 
the way to the extended used of exosomes in cell-free regenerative medicine25,26. In this scenery, treatment with 
AMSCs-derived exosomes may have significant advantages, since they may replace live cells administration, mit-
igating many of the safety concerns and limitations associated with the transplantation of viable replicating cells.
In this study, we investigated the immunomodulatory properties of AMSCs-derived exosomes, discovering 
that an inflammatory stimulus activate AMSCs and can induce the release of exosomes with immunosuppressive 
abilities, since they are able to polarize macrophages towards the anti-inflammatory M2 phenotype. Our results 
suggest that the ability of AMSCs-derived exosomes to modulate the differentiation of macrophages is not consti-
tutive, but rather activated by signals derived from a pro-inflammatory microenvironment.
There are evidences suggesting that MSCs produce immune modulatory and regenerative factors in response 
to inflammatory stimuli, in fact, it may be possible to enhance or suppress certain functions of MSCs by con-
trolling their culture conditions, in particular, priming of MSCs with IFNγ and TNFα successfully improved their 
immunomodulatory functions27. Specifically, treatment with IFNγ up-regulated several genes involved in immu-
nomodulation, such as HLA-DRA, CD274B7, IDO, VCAM1, ICAM2, and chemokines such as CCL8, CXCL9 
and CXCL1028. In addition, an in vitro model showed that, after priming with TNFα plus IFNγ, MSCs were less 
potent at increasing cytokine production by activated PBMCs and more effective at inhibiting T-cell prolifera-
tion29. In our study, in agreement with previous data27, we demonstrated that AMSCs, stimulated with increasing 
concentrations of IFNγ and TNFα, release immunomodulatory factors.
We observed that, pre-treatment with pro-inflammatory cytokines induced AMSCs expression of IDO, which 
probably inhibits cells proliferation in an autocrine manner, as proposed by Croitoru-Lamoury et al.5. Moreover, 
we found that cytokines treatment induce the production of other immunomodulatory mediators, such as PGE2 
and IL-10 as well as the chemokine CCL-2, which is critical for the chemotaxis of monocytes. It has been sug-
gested that by this mechanism, chemokine recruits monocytes into close proximity to MSCs, whereupon the 
immunosuppressive factors produced locally, may influence the inflammatory process30.
Recently, it has been proposed that the immunomodulatory activity of MSCs is mediated by the synergism 
between secreted small molecules and exosomes14,31,32. In our study, we characterized AMSCs-derived exosomes, 
investigating in particular the influence of an inflammatory stimulus on their miRNA cargo and downstream 
functions. Of note, we demonstrated that only monocytes cultured in the presence of exosomes produced by 
cytokines-activated AMSCs, are able to transdifferentiate M1 pro-inflammatory to M2 anti-inflammatory 
macrophages.
It has been already documented that MSCs can educate macrophages to adapt to an anti-inflammatory and 
immune suppressive phenotype33 and can induce the differentiation of human M2 by direct and indirect contact 
mechanisms34, but little is known about the possible role of released exosomes and previous study on their immu-
nosuppressive properties are controversial.
It has been reported that exosomes released from MSCs exert an inhibitory effect in differentiation and acti-
vation of T cells16 and activate monocytes to produce high levels of anti-inflammatory cytokines, finally polar-
izing activated CD4 + T cell into regulatory T cell15. On the other hands, it has been reported that extracellular 
vesicles produced by bone marrow- and adipose tissue-derived mesenchymal stromal cells failed to suppress 
lymphocyte proliferation18, suggesting that cell-cell contact may play an important role on the immunosuppres-
sive potential mediated by MSCs. In the light of our data, it can be assumed that the discrepancy in literature data 
is probably due to the low/absent immunosuppressive potential of exosomes produced by unstimulated MSCs, 
since we demonstrated that such immunosuppressive effect is evident only when AMSCs are pre-activated by a 
pro-inflammatory stimulus.
Recently, it has been demonstrated that MSCs can release small RNAs via exosomes, which are increasingly 
implicated in intracellular communications35 and may participate in the resolution of chronic inflammation, 
enhancing the curative effects of MSCs36.
In order to explore whether AMSCs-derived exosomes exert their specific immunomodulatory effects through 
specific miRNAs, we evaluated the expression of miRNA involved in the regulation of macrophage polariza-
tion20, reporting an increase in the expression of miRNAs regulating the M2 phenotype (miR-34a-5p, miR21, 
miR146a-5p) in exosomes produced by pre-activated AMSCs compared to those released by untreated cells. In 
particular, miR-34 inhibits the transcription of pro-inflammatory cytokines targeting Notch121, while miR-146 
targets NF-kB signalling mediators such as IRAK1 and TRAF6 and promote the expression of M2-associated 
genes37. Regarding miR-21, there are controversial opinion on its role in mediating macrophage polarization. It 
has been proposed that in early stage of inflammation, pri-miR-21 exerts pro-inflammatory effects and, through 
STAT3 expression upregulation, polarizes macrophages towards the M1 phenotype38. By contrast, at the resolu-
tion phase, mature miR-21 regulates the anti-inflammatory response and polarize macrophages towards the M2 
phenotype, suppressing Sirp-β1, that is a MEK/ERK1/2 pathway activator23. We also showed that exosomes pro-
duced by pre-activated AMSCs shuttled miR-146, which might participate in macrophage polarization toward M2 
phenotype by targeting IRAK1. In line with our results, it has been hypothesized that miR-21, miR-146a and miR-
181, which displayed the most significant and highest expression in MSCs-derived exosomes, could modulate the 
expression of pro-inflammatory genes, thus reducing or delaying inflammation and enhance wound healing36. 
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Of note, it has been reported that miR-146a was strongly upregulated in exosomes released by MSCs stimulated 
with IL-1β and it contributes to mitigate inflammation and increase survival in septic mice39. Finally, it is pos-
sible to hypothesize that, in addition to our documented miRNA-mediated effect, other molecules carried by 
exosomes, could play a role in macrophages polarization. In particular, several studies have shown that exosomes 
derived from MSCs harbor cytokines and growth factors, such as TGFβ1, interleukin-6 (IL-6), IL-10, and hepat-
ocyte growth factor (HGF), which have been shown to contribute to immunoregulation40,41.
In conclusion, the present study demonstrates that AMSCs release exosomes with measurable immuno-
suppressive effects only after pre-activation with pro-inflammatory cytokines, simulating an inflammatory 
microenvironment. As a matter of fact, exosomes released from pre-activated AMSCs show the capability to 
switch macrophages to M2-like phenotype by shuttling miRNAs regulating macrophages polarization. Our data 
strongly suggest that an inflammatory stimulus may be fundamental to induce the release of immunotherapeutic 
exosomes from AMSCs.
Methods
Adipose mesenchymal stem cells isolation and culture. Adipose mesenchymal stem cells (AMSCs) 
were isolated from adipose tissue obtained by lipoaspirates. A total number of six lipoaspirate samples were col-
lected after informed written consent of donors. Ethical approval was obtained from the Medical Research Ethics 
Committee of the Centro di Riferimento Oncologico, IRCCS, Aviano, Italy (Consent CRO-2016-30).
Lipoaspirates were enzymatically dissociated using a 0.05% collagenase II solution for 20 minutes at 37 °C 
(Worthington) and, after neutralization of the enzyme, were centrifuged at 500 × g for 5 minutes and filtered 
through a 70 μm nylon mesh (Merck Millipore). Cells were seeded in minimum essential medium-α (MEM-α) 
supplemented with 10% FBS (Gibco), penicillin/streptomycin solution (10 mL/L), alanine/glutamine solution 
(2 mM), human epidermal growth factor (10 ng/ml), insulin solution (10 μg/ml), 2-fosfo-L-ascorbic acid, triso-
dium salt (100 μM) and dexamethasone (0.01 μM) (all from Sigma-Aldrich). Culture were kept at 37 °C, 5% CO2 
and 95% humidity and cells were characterized by flow cytometry using MSCs positive markers (CD29, CD73, 
CD90 and CD105) and hematopoietic negative markers (CD34 and CD45) as described previously42. Cells were 
used for experiment between passage 2 and 5.
All methods of analysis were performed in accordance with the relevant guidelines and regulations with 
appropriate quality control.
Activation of adipose mesenchymal stem cells with IFNγ and TNFα. To activate AMSCs with 
inflammatory factors, cells were seeded at density of 15,000 cells/cm2 and after 24 hours supernatant was replaced 
with fresh culture medium supplemented with 5% certified exosomes-free serum (Gibco) with recombinant 
human IFNγ and TNFα (Prepotech) at different concentrations (10, 20 and 40 ng/ml). The concentration 
10 ng/ml corresponds to 200U/ml. After 48 hours, AMSCs were harvested and cell proliferation/viability was 
determined by trypan blue exclusion assay. For flow cytometry analysis, AMSCs were fixed and permeabilized 
with intracellular Fix/Perm solution (eBiosciences), incubated with FITC-conjugated indoleamine-pyrrole 
2,3-dioxygenase (IDO) antibody (eBiosciences) for 15 min and then washed twice with PBS. Flow cytometry was 
carried out on the FACSCalibur (Becton Dickson) and data analysed using Flowing software. Supernatants were 
also harvested, centrifuged for 10 minutes at 14,000 × g and stored at −80 °C for exosomes isolation or cytokines 
detection. The concentration of IL-6, IL-10, IL-8 and CCL-2 was determined with a magnetic beads-based multi-
plex assay (Bio-plex Assay, Bio-Rad Laboratories), while prostaglandin E2 release (PGE2) was quantified with an 
enzyme-linked immunosorbent assay (ELISA) kit (Invitrogen).
AMSCs-derived exosomes isolation and characterization. Exosomes were isolated from AMSCs 
supernatants by polymer precipitation methods with (ExoQuick-TC System Biosciences) as described previ-
ously43. The exosomes-containing pellet was resuspended in PBS buffer or lysis buffer for subsequent analysis. 
AMSCs-derived exosomes number was determined using the Exocet kit (System Biosciences), according to man-
ufacturer’s instructions. Briefly, exosomes were lysed using a gentle lysis solution to preserve the enzymatic activ-
ity of the exosomal Acetylcholinesterase (AChE) enzyme. A standard curve was generated using known numbers 
of exosomes (as measured by NanoSight) and calibrated with a recombinant AChE enzyme standard solution 
provided in the kit.
The size distribution of the exosomes collected was determined using a qNano (Izon) nanopore-based 
exosome detection system, according to the manufacturer’s instructions.
AMSCs lysate, AMSCs-derived exosomes and Exoquick-derived supernatants were analysed for the expres-
sion of exosomal markers and contaminants by immunoblotting. Anti-CD9 (1:1000, System BioScience), 
anti-CD63 (1:1000, LS Bio), anti-CD81 (1:500, Abcam), anti-TSG101 (1:500, Abcam), anti-calnexin (1:1000 Enzo 
Life Technologies), anti-GRP94 (1:1000 Genetex) and anti-RISC (1:1000 Abcam) were used as primary antibod-
ies. Horseradish peroxidase (HRP)-conjugated IgG antibody (1:1000, Dako) was used as the secondary antibody.
To ensure that IFNγ and TNFα were not present in our exosome preparation as contaminants, the culture 
medium supplemented with cytokines at different concentrations (10, 20 and 40 ng/ml) was incubated with 
Exoquick as described above and concentration of IFNγ and TNFα was measured by magnetic beads-based 
multiplex assay.
Exosomal RNA isolation, library preparation/sequencing and RT-PCR. To preserve small RNAs, total 
RNA was extracted from 5 × 109 AMSCs-derived exosomes, using mirVana PARIS Kit (Life Technologies), adding 
cel-miR39 spike-in as exogenous control (ThermoFisher Scientific). Extracted RNA quality and quantity was evalu-
ated by NanoDrop™ 1000 Spectrophotometer (ThermoFisher Scientific) and was stored at −80 °C until use.
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For miRNA profiling analysis, a pool of AMSCs-derived exosomes obtained in five different purification 
was examined. ‘TruSeq SmallRNA Sample Prep kit’ (Illumina) has been used for library preparation follow-
ing the manufacturer’s instructions. Both RNA samples and final libraries were quantified by using the Qubit 
2.0 Fluorometer (Invitrogen) and quality tested by Agilent 2100 Bioanalyzer RNA Nano assay (Agilent tech-
nologies). Libraries were then processed with Illumina cBot for cluster generation on the flowcell, following the 
manufacturer’s instructions and sequenced on single-end mode on NextSeq 500 (Illumina, San Diego, CA). The 
CASAVA 1.8.2 version of the Illumina pipeline was used to processed raw data for both format conversion and 
de-multiplexing.
The relative concentrations of miRNAs involved in regulation of macrophages M1 (has-miR-21-5p, has-miR-
127-3p and has-miR-155-5p) and M2 (has-miR-34a-5p, has-miR124-3p, has-miR135b-5p and hsa-miR146a-5p) 
polarization were assessed using TaqMan® Advanced miRNA Assays (ThermoFisher Scientific), according to 
manufacturer’s instructions, except for cDNA templates that were diluted 1:2 instead of recommended 1:10.
Real-time reaction was performed on the Applied Biosystems QuantStudio 3 System. MiRNA relative con-
centrations were normalized using relative standard curve method obtained by serial dilutions of cel-miR39 
(1nM-100fM).
Monocytes isolation and differentiation into M1 macrophages. Human peripheral blood mono-
nuclear cells (PBMCs) were isolated from EDTA-uncoagulated blood of blood donors by Ficoll gradient centrif-
ugation (Millipore). Monocytes were separated from PBMCs by negative selection using a human CD14+ cell 
enrichment kit (StemCell Technologies) according to the manufacturer’s instructions and resuspended in RPMI 
medium supplemented with 10% heat inactivated fetal bovine serum (FBS), 1% glutamine, 1% pyruvate, 1% 
non-essential aminoacid, 1% penicillin/streptomycin, 1% Hepes (all from Euroclone). To remove the exosomal 
fraction present in FBS, serum was ultracentrifuged for 4 hours at 100,000 × g. Purity of monocytes was over 95% 
as judged by staining with anti-CD14 (eBiosciences) (data not shown).
For macrophages differentiation, CD14+ monocytes were seeded in multiwell plates at 5 × 105/cm2 in com-
plete RPMI medium supplemented with 100 ng/ml granulocyte macrophage-colony stimulating factor (GM-CSF, 
Peprotech) in presence of 8 × 108 AMSC-derived exosomes; medium was changed completely every 3 days. On 
day 9, macrophages was harvested with TrypLE TM express detachment solution (Gibco) and characterized by flow 
cytometry for the expression of M1 and M2 macrophages markers using CD80, CD206 and CD163 antibodies 
(eBiosciences). Macrophages were also lysed in RIPA buffer and expression of IRAK1, Notch1 and SIRPb1 was ana-
lysed by immunoblotting. Anti-IRAK1 (1:1000, Cell Signalling), anti-β-actin (1:5000, Cell Signalling), anti-Notch1 
(1:500, Cell signalling) and anti-Sirp-β1 (1:200, Santa Cruz Biotecnologies) were used as primary antibodies. 
Horseradish peroxidase (HRP)-conjugated IgG antibody (1:1000, Dako) was used as the secondary antibody.
Statistical methods. Data are reported as mean ± standard deviation. Statistical analysis has been 
performed using GraphPad Software (version 7). Data were tested for normal distribution using the 
Kolmogorov-Smirnov test. Repeated measurements were analysed by one-way analysis of variance followed by 
the Bonferroni or Dunnett post test. P values < 0.05 was considered significant.
References
 1. Farini, A., Sitzia, C., Erratico, S., Meregalli, M. & Torrente, Y. Clinical Applications of Mesenchymal Stem Cells in Chronic Diseases. 
Stem Cells Int. 2014, 1–11 (2014).
 2. Glenn, J. D. & Whartenby, K. A. Mesenchymal stem cells: Emerging mechanisms of immunomodulation and therapy. World J. Stem 
Cells 6, 526–39 (2014).
 3. Gao, F. et al. Mesenchymal stem cells and immunomodulation: current status and future prospects. Cell Death Dis. 7, e2062 (2016).
 4. Wang, Y., Chen, X., Cao, W. & Shi, Y. Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic 
implications. Nat. Immunol. 15, 1009–1016 (2014).
 5. Croitoru-Lamoury, J. et al. Interferon-γ regulates the proliferation and differentiation of mesenchymal stem cells via activation of 
indoleamine 2,3 dioxygenase (IDO). PLoS One 6, e14698 (2011).
 6. Tu, Z., Li, Q., Bu, H. & Lin, F. Mesenchymal stem cells inhibit complement activation by secreting factor H. Stem Cells Dev. 19, 
1803–9 (2010).
 7. Noone, C., Kihm, A., English, K., O’Dea, S. & Mahon, B. P. IFN-γ stimulated human umbilical-tissue-derived cells potently suppress 
NK activation and resist NK-mediated cytotoxicity in vitro. Stem Cells Dev. 22, 3003–14 (2013).
 8. Ryan, J. M., Barry, F., Murphy, J. M. & Mahon, B. P. Interferon-gamma does not break, but promotes the immunosuppressive 
capacity of adult human mesenchymal stem cells. Clin. Exp. Immunol. 149, 353–63 (2007).
 9. Kwon, Y. W. et al. Tumor necrosis factor-α-activated mesenchymal stem cells promote endothelial progenitor cell homing and 
angiogenesis. Biochim. Biophys. Acta 1832, 2136–44 (2013).
 10. Doorn, J., Moll, G., Le Blanc, K., van Blitterswijk, C. & de Boer, J. Therapeutic applications of mesenchymal stromal cells: paracrine 
effects and potential improvements. Tissue Eng. Part B. Rev. 18, 101–15 (2012).
 11. Timmers, L. et al. Human mesenchymal stem cell-conditioned medium improves cardiac function following myocardial infarction. 
Stem Cell Res. 6, 206–14 (2011).
 12. Camussi, G., Deregibus, M. C. & Cantaluppi, V. Role of stem-cell-derived microvesicles in the paracrine action of stem cells: Figure 
1. Biochem. Soc. Trans. 41, 283–287 (2013).
 13. Camussi, G., Deregibus, M. C. & Tetta, C. Paracrine/endocrine mechanism of stem cells on kidney repair: role of microvesicle-
mediated transfer of genetic information. Curr. Opin. Nephrol. Hypertens. 19, 7–12 (2010).
 14. Yu, B., Zhang, X. & Li, X. Exosomes derived from mesenchymal stem cells. Int. J. Mol. Sci. 15, 4142–57 (2014).
 15. Zhang, B. et al. Mesenchymal stem cells secrete immunologically active exosomes. Stem Cells Dev. 23, 1233–44 (2014).
 16. Blazquez, R. et al. Immunomodulatory Potential of Human Adipose Mesenchymal Stem Cells Derived Exosomes on in vitro 
Stimulated T Cells. Front. Immunol. 5, 556 (2014).
 17. Chen, W. et al. Immunomodulatory effects of mesenchymal stromal cells-derived exosome. Immunol. Res. 64, 831–40 (2016).
 18. Gouveia de Andrade, A. V. et al. Extracellular vesicles secreted by bone marrow- and adipose tissue-derived mesenchymal stromal 
cells fail to suppress lymphocyte proliferation. Stem Cells Dev. 24, 1374–6 (2015).
 19. McWhorter, F. Y., Wang, T., Nguyen, P., Chung, T. & Liu, W. F. Modulation of macrophage phenotype by cell shape. Proc. Natl. Acad. 
Sci. 110, 17253–17258 (2013).
www.nature.com/scientificreports/
1 1SCientifiC REPORts |  (2018) 8:13325  | DOI:10.1038/s41598-018-31707-9
 20. Essandoh, K., Li, Y., Huo, J. & Fan, G.-C. MiRNA-Mediated Macrophage Polarization and its Potential Role in the Regulation of 
Inflammatory Response. SHOCK 46, 122–131 (2016).
 21. Jiang, P. et al. MiR-34a inhibits lipopolysaccharide-induced inflammatory response through targeting Notch1 in murine 
macrophages. Exp. Cell Res. 318, 1175–1184 (2012).
 22. Taganov, K. D., Boldin, M. P., Chang, K.-J. & Baltimore, D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor 
targeted to signaling proteins of innate immune responses. Proc. Natl. Acad. Sci. USA 103, 12481–6 (2006).
 23. Caescu, C. I. et al. Colony stimulating factor-1 receptor signaling networks inhibit mouse macrophage inflammatory responses by 
induction of microRNA-21. Blood 125, e1–13 (2015).
 24. Glenn, J. D. & Whartenby, K. A. Mesenchymal stem cells: Emerging mechanisms of immunomodulation and therapy. World J. Stem 
Cells 6, 526 (2014).
 25. Rani, S., Ryan, A. E., Griffin, M. D. & Ritter, T. Mesenchymal Stem Cell-derived Extracellular Vesicles: Toward Cell-free Therapeutic 
Applications. Mol. Ther. 23, 812–23 (2015).
 26. Vishnubhatla, I., Corteling, R., Stevanato, L., Hicks, C. & Sinden, J. The Development of Stem Cell-derived Exosomes as a Cell-free 
Regenerative Medicine. J. Circ. Biomarkers 1 https://doi.org/10.5772/58597 (2014).
 27. Madrigal, M., Rao, K. S. & Riordan, N. H. A review of therapeutic effects of mesenchymal stem cell secretions and induction of 
secretory modification by different culture methods. J. Transl. Med. 12, 260 (2014).
 28. Lee, M. W. et al. Strategies to improve the immunosuppressive properties of human mesenchymal stem cells. Stem Cell Res. Ther. 6, 
179 (2015).
 29. Cuerquis, J. et al. Human mesenchymal stromal cells transiently increase cytokine production by activated T cells before suppressing 
T-cell proliferation: effect of interferon-γ and tumor necrosis factor-α stimulation. Cytotherapy 16, 191–202 (2014).
 30. Ren, G. et al. Mesenchymal Stem Cell-Mediated Immunosuppression Occurs via Concerted Action of Chemokines and Nitric 
Oxide. Cell Stem Cell 2, 141–150 (2008).
 31. Pashoutan Sarvar, D., Shamsasenjan, K. & Akbarzadehlaleh, P. Mesenchymal Stem Cell-Derived Exosomes: New Opportunity in 
Cell-Free Therapy. Adv. Pharm. Bull. 6, 293–299 (2016).
 32. Lai, R. C., Yeo, R. W. Y. & Lim, S. K. Mesenchymal stem cell exosomes. Semin. Cell Dev. Biol. 40, 82–88 (2015).
 33. Eggenhofer, E. & Hoogduijn, M. J. Mesenchymal stem cell-educated macrophages. Transplant. Res. 1, 12 (2012).
 34. Abumaree, M. H. et al. Human Placental Mesenchymal Stem Cells (pMSCs) Play a Role as Immune Suppressive Cells by Shifting 
Macrophage Differentiation from Inflammatory M1 to Anti-inflammatory M2 Macrophages. Stem Cell Rev. Reports 9, 620–641 
(2013).
 35. Baglio, S. R. et al. Human bone marrow- and adipose-mesenchymal stem cells secrete exosomes enriched in distinctive miRNA and 
tRNA species. Stem Cell Res. Ther. 6, 127 (2015).
 36. Ti, D., Hao, H., Fu, X. & Han, W. Mesenchymal stem cells-derived exosomal microRNAs contribute to wound inflammation. Sci. 
China. Life Sci. 59, 1305–1312 (2016).
 37. Vergadi, E. et al. Akt2 deficiency protects from acute lung injury via alternative macrophage activation and miR-146a induction in 
mice. J. Immunol. 192, 394–406 (2014).
 38. Wang, Z. et al. MicroRNA 21 Is a Homeostatic Regulator of Macrophage Polarization and Prevents Prostaglandin E2-Mediated M2 
Generation. PLoS One 10, e0115855 (2015).
 39. Song, Y. et al. Exosomal miR-146a Contributes to the Enhanced Therapeutic Efficacy of Interleukin-1β-Primed Mesenchymal Stem 
Cells Against Sepsis. Stem Cells 35, 1208–1221 (2017).
 40. Burrello, J. et al. Stem Cell-Derived Extracellular Vesicles and Immune-Modulation. Front. cell Dev. Biol. 4, 83 (2016).
 41. Lai, R. C. et al. Proteolytic Potential of the MSC Exosome Proteome: Implications for an Exosome-Mediated Delivery of Therapeutic 
Proteasome. Int. J. Proteomics 2012, 1–14 (2012).
 42. Domenis, R. et al. Adipose tissue derived stem cells: in vitro and in vivo analysis of a standard and three commercially available cell-
assisted lipotransfer techniques. Stem Cell Res. Ther. 6, 2 (2015).
 43. Domenis, R. et al. Systemic T Cells Immunosuppression of Glioma Stem Cell-Derived Exosomes Is Mediated by Monocytic 
Myeloid-Derived Suppressor Cells. PLoS One 12, e0169932 (2017).
Acknowledgements
This project was partially supported by an unrestricted grant from VivaBioCell S.p.A.
Author Contributions
R.D. carried out most of the experiments, critically contributed to the interpretation of the results and wrote 
the manuscript. A.C. contributed to the experimental design and performed experiments. S.Q., C.P., M.M. and 
A.V. performed experiments. P.C.P. was responsible for provision of study material. M.F. contributed to the 
experimental design and to editing the manuscript. K.R.N. contributed to interpretation of the results and to 
critical reading of the manuscript. P.S.S supervised the project. F.C provided resources, designed and supervised 
the project. All authors critically read and approved the final version of the manuscript.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-31707-9.
Competing Interests: The authors declare no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2018
